Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.6 - $5.16 $132,480 - $262,922
50,954 Added 5.93%
910,851 $6.16 Million
Q2 2022

Aug 12, 2022

SELL
$2.46 - $5.2 $138,721 - $293,233
-56,391 Reduced 6.15%
859,897 $4.03 Million
Q1 2022

May 13, 2022

SELL
$4.16 - $9.08 $449,300 - $980,685
-108,005 Reduced 10.54%
916,288 $4.35 Million
Q4 2021

Feb 14, 2022

SELL
$7.65 - $11.38 $469,166 - $697,924
-61,329 Reduced 5.65%
1,024,293 $8.71 Million
Q3 2021

Nov 12, 2021

BUY
$9.93 - $13.59 $1.23 Million - $1.68 Million
123,695 Added 12.86%
1,085,622 $12.6 Million
Q2 2021

Aug 13, 2021

BUY
$11.87 - $15.96 $11.4 Million - $15.4 Million
961,927 New
961,927 $12.1 Million

About Akouos, Inc.


  • Ticker AKUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,929,000
  • Description
  • Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...
More about AKUS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.